ClinicalTrials.gg
Not yet recruitingNCT06658964Updated Oct 26, 2024

Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects

A Phase 1 interventional study of Cohort 1: JMKX003142 and itraconazole and Cohort 2: JMKX003142 and rifampicin in ADPKD (autosomal Dominant Polycystic Kidney Disease), sponsored by Jemincare. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Jemincare · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.

02

Conditions studied

  • ADPKD (autosomal Dominant Polycystic Kidney Disease)
03

In context

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

This study's planned enrollment of 48 is close to the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.

Browse Polycystic Kidney, Autosomal Dominant studies →

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understand the research content, process, and potential risks of this trial, voluntarily participate in the clinical trial and sign the ,
  • Healthy male and female subjects aged ≥18 years and ≤45 years old, Male weight ≥50kg, female weight ≥45kg, ≥19 kg/m2 and ≤28 kg/m2,
  • The health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead , all of which were determined by the investigator to be normal or not .

Exclusion criteria

Exclusion Criteria:

  • surface antigen, antibody, , or syphilis are positive during screening,
  • At the time of screening, the vital signs are within the following ranges: systolic blood pressure \<90 mmHg or >140 mmHg, diastolic blood pressure \<50 mmHg or >90 mmHg, pulse \<50 bpm or >100 bpm and ear temperature 37.5℃or\<35℃,
  • More than 5 cigarettes per day during the 3 months prior to screening, Or were unable to quit smoking/containing tobacco products during the trial,
  • Have special requirements for diet and cannot comply with the diet provided and corresponding regulations.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Cohort 1:JMKX003142 and itraconazole

    Interaction between JMKX003142 and itraconazole

    Drug: Cohort 1: JMKX003142 and itraconazole

  • Experimental
    Cohort 2:JMKX003142 and rifampicin

    Interaction between JMKX003142 and rifampicin

    Drug: Cohort 2: JMKX003142 and rifampicin

Interventions

  • DrugCohort 1: JMKX003142 and itraconazole

    Drug pages: JMKX003142 · Itraconazole

    JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning. Itraconazole:Dose: 200mg once;Day5-Day7 and Day9-Day11, QD

  • DrugCohort 2: JMKX003142 and rifampicin

    Drug pages: JMKX003142 · Rifampin

    JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning. Rifampicin:Dose: 600mg once;Day5-Day13 and Day15-Day17, QD

06

What researchers measure

Primary outcomes

  1. Cmax of JMKX003142 in plasma

    Cmax of JMKX003142 when JMKX003142 administered with or without itraconazole/rifampicin

    Time frame: approximately 5 days after JMKX003142 administered

  2. AUC of JMKX003142 in plasma

    AUC of JMKX003142 when JMKX003142 administered with or without itraconazole/rifampicin

    Time frame: approximately 5 days after JMKX003142 administered

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Dec 2024, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Oct 26, 2024
StartEst.
Nov 5, 2024
Primary completionEst.
Dec 10, 2024
CompletionEst.
Mar 21, 2025
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06658964
Lead sponsor
Jemincare
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 26, 2024
Start date
Nov 5, 2024 (estimated)
Primary completion
Dec 10, 2024 (estimated)
Completion
Mar 21, 2025 (estimated)
Last update
Oct 26, 2024

Study contacts

Jianping Su
Contact
sujianping@jemincare.com
86+15162481262
Leilei Zhu
principal investigator · Shuguang Hospital Affiliated with Shanghai University of TCM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: JMKX003142 · Itraconazole · Rifampin

Start the discussion